上半年亏损超4000万元，深圳这家医疗企业递表港交所

Core Viewpoint - The article discusses the listing application of Shenzhen Maikedian Biomedical Technology Co., Ltd. on the Hong Kong Stock Exchange, highlighting its significance in expanding market and research capabilities [1][2]. Company Overview - Maikedian is a global provider of medical solutions, offering a comprehensive product portfolio that meets clinical needs across various healthcare settings. The company has commercialized over 50 life support products, 80 minimally invasive products, and 210 in vitro diagnostic products, with a presence in over 140 countries and regions [4]. Financial Performance - The company has faced losses in recent years, with reported revenues of approximately RMB 917 million, RMB 1.313 billion, RMB 1.399 billion, and RMB 787 million for the six months ending June 30 in 2022, 2023, 2024, and 2025 respectively. The corresponding losses were RMB 226.16 million, RMB 64.51 million, RMB 96.62 million, and RMB 40.97 million [5][7]. Product Segments - In the life support segment, Maikedian has developed innovative products, achieving the top sales ranking in China for infusion workstations from 2018 to 2024 and for enteral nutrition pumps from 2021 to 2024 [6]. - The minimally invasive segment has shown growth, with sales increasing from RMB 38.6 million in 2022 to RMB 58.65 million in 2023, and further to RMB 72.13 million in 2024. The company attributes this growth to an expanded customer base and increased sales volume [8]. - In vitro diagnostic revenue rose from RMB 11.55 million in 2022 to RMB 16.26 million in 2023, and then to RMB 18.4 million in 2024, driven by an expanding product portfolio and market coverage [9].